Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Glioblastoma 3Brain Neoplasms 3Glioma 2Thyroid Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Neurologic Manifestations 1Neoplasms, Neuroepithelial 1Neoplasm Metastasis 1Lymphoma 1Leukemia 1Head and Neck Neoplasms 1HTLV-I Infections 1Gliosarcoma 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Astrocytoma 1

Interventions

Bevacizumab 3Temozolomide 2Sorafenib 2pembrolizumab 1Valproic Acid 1Therapeutics 1Sildenafil Citrate 1Radiosurgery 1Irinotecan 1Equipment and Supplies 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurologic Manifestations × Valproic Acid × Clear all
NCT01817751 2024-07-17

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Virginia Commonwealth University

Phase 2 Completed
47 enrolled 13 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neurologic Manifestations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡